Harbin Pharmaceutical Group Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Harbin Pharmaceutical Group.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

Jun 25

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

May 25

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Apr 17

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Harbin Pharmaceutical Group no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SHSE:600664 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	16,219	613	210	323	N/A
6/30/2024	15,895	556	400	492	N/A
3/31/2024	15,667	450	411	496	N/A
12/31/2023	15,457	395	863	950	N/A
9/30/2023	15,312	599	1,218	1,284	N/A
6/30/2023	15,096	526	925	988	N/A
3/31/2023	14,406	487	576	650	N/A
12/31/2022	13,809	465	532	622	N/A
9/30/2022	13,053	41	34	137	N/A
6/30/2022	12,812	151	-252	-157	N/A
3/31/2022	13,156	389	73	166	N/A
12/31/2021	12,802	371	-239	-162	N/A
9/30/2021	12,879	-219	-903	-811	N/A
6/30/2021	12,385	-402	-511	-402	N/A
3/31/2021	11,258	-808	-1,015	-902	N/A
12/31/2020	10,788	-1,078	-846	-728	N/A
9/30/2020	11,009	-321	-289	-209	N/A
6/30/2020	11,118	-235	-334	-271	N/A
3/31/2020	11,661	14	-162	-107	N/A
12/31/2019	11,825	56	-324	-285	N/A
9/30/2019	11,174	107	293	390	N/A
6/30/2019	10,696	-59	318	418	N/A
3/31/2019	10,630	61	262	372	N/A
12/31/2018	10,814	346	579	693	N/A
9/30/2018	10,910	386	111	197	N/A
6/30/2018	11,484	422	N/A	-36	N/A
3/31/2018	11,790	501	N/A	202	N/A
12/31/2017	12,018	407	N/A	149	N/A
9/30/2017	12,993	441	N/A	598	N/A
6/30/2017	13,180	757	N/A	1,110	N/A
3/31/2017	13,761	737	N/A	1,833	N/A
12/31/2016	14,127	788	N/A	2,778	N/A
9/30/2016	13,662	789	N/A	3,179	N/A
6/30/2016	13,830	584	N/A	3,553	N/A
3/31/2016	14,435	515	N/A	2,929	N/A
12/31/2015	15,856	580	N/A	1,660	N/A
9/30/2015	16,038	324	N/A	899	N/A
6/30/2015	16,622	302	N/A	498	N/A
3/31/2015	16,290	238	N/A	945	N/A
12/31/2014	16,509	247	N/A	1,136	N/A
9/30/2014	17,382	230	N/A	715	N/A
6/30/2014	18,019	307	N/A	142	N/A
3/31/2014	18,402	107	N/A	-9	N/A
12/31/2013	18,092	169	N/A	142	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if 600664's forecast earnings growth is above the savings rate (2.9%).

Beneficios vs. Mercado: Insufficient data to determine if 600664's earnings are forecast to grow faster than the CN market

Beneficios de alto crecimiento: Insufficient data to determine if 600664's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if 600664's revenue is forecast to grow faster than the CN market.

Ingresos de alto crecimiento: Insufficient data to determine if 600664's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if 600664's Return on Equity is forecast to be high in 3 years time

Harbin Pharmaceutical Group Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.053 in 3Q 2023)

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 22%

Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.022 in 2Q 2023)

High number of new and inexperienced directors

Investor sentiment improves as stock rises 18%

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings

We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease

Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024

First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.05 in 1Q 2023)

Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think

Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 18%

Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024

Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)

Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)

Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) dropped from S&P Global BMI Index

New 90-day low: CN¥2.84

New 90-day low: CN¥3.09

New 90-day low: CN¥3.22

Third quarter earnings released

New 90-day low: CN¥3.33

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

First half earnings released

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento